COMPASS Pathways plc Stock Price Today, CMPS Stock Price Chart

Based on our COMPASS Pathways plc stock forecast, it’s now a bad time to buy CMPS stock because it’s trading 21.28% above our forecast. Money Flow Uptick/Downtick RatioMoney flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an “uptick” in price and the value of trades made on a “downtick” in price. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades. Net money flow is the value of uptick trades minus the value of downtick trades. Discuss news and analysts’ price predictions with the investor community. It is currently as good a time as ever for long-term investors to buy stocks.

Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Tuesday, April 04, 2023, and so far it has fallen -1.31%. Further fall is indicated until a new bottom pivot has been found. SVB Securities analyst Andrew Berens maintained a Buy rating on Compass Therapeutics (CMPX – Research Report) on November 9 and set a price target of $11.00.

The purpose of a moving average is to smooth price action over a certain amount of time. Moving averages are a lagging indicator which means they are based on previous price action. In the table below you can find two types of moving averages, simple moving average and exponential moving average . In summary, COMPASS Pathways plc has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. We sell different types of products and services to both investment professionals and individual investors.

COMPASS Pathways to Hold Virtual Capital Market Day on 12 October 2022

Compass Pathways’s market cap is calculated by multiplying CMPS’s current stock price of $10.55 by CMPS’s total outstanding shares of 42,763,816. Compass Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 2,130,000 shares, an increase of 17.7% from the February 28th total of 1,810,000 shares.

Brokerage https://1investing.in/ for alternative assets available on Public are offered by Dalmore Group, LLC (“Dalmore”), member of FINRA & SIPC. “Alternative assets,” as the term is used at Public, are equity securities that have been issued pursuant to Regulation A of the Securities Act of (“Regulation A”). These investments are speculative, involve substantial risks , and are not FDIC or SIPC insured. Alternative Assets purchased on the Public platform are not held in an Open to the Public Investing brokerage account and are self-custodied by the purchaser. The issuers of these securities may be an affiliate of Public, and Public may earn fees when you purchase or sell Alternative Assets. For more information on risks and conflicts of interest, see these disclosures.

hyperinflation: definition, causes, effects, examples Therapeutics has a short interest ratio (“days to cover”) of 5.7. This is a great company, but it need some time to fully expand their potential…if the world is ready for the medicine of the future, this stock will explode…Hope this great company can help many peoples in the world… All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns.

COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights

Some traders try to identify candlestick patterns when making a stock price prediction to try and get an edge over the competition. Some candlestick formations are seen as likely to forecast bullish price action, while others are seen as bearish. In addition to the simple moving average , traders also use another type of moving average called the exponential moving average .

These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters. According to analysts’ consensus price target of $9.05, Compass Therapeutics has a forecasted upside of 167.0% from its current price of $3.39.

Latest On Compass Pathways PLC

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Upgrade to MarketBeat All Access to add more stocks to your watchlist.

Moving averages are among the most popular COMPASS Pathways plc stock prediction tools. As the name suggests, a moving average provides the average closing price for CMPS stock over a selected time frame, which is divided into a number of periods of the same length. For example, a 12-day simple moving average for CMPS is a sum of CMPS’s closing prices over the last 12 days which is then divided by 12. The average price estimated by analysts for CMPS is $41.55, which is $31.7 above than the current price. The public float for CMPS is 21.94M, and at present, short sellers hold a 20.80% of that float.

COMPASS Pathways to participate in upcoming 22nd Annual Needham Virtual Healthcare Conference

JSI and Jiko Bank are not affiliated with Public Holdings, Inc. (“Public”) or any of its subsidiaries. None of these entities provide legal, tax, or accounting advice. You should consult your legal, tax, or financial advisors before making any financial decisions. This material is not intended as a recommendation, offer, or solicitation to purchase or sell securities, open a brokerage account, or engage in any investment strategy.

The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high. 5 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for COMPASS Pathways in the last year. The consensus among Wall Street equities research analysts is that investors should “buy” CMPS shares. Compass Pathways PLC’s stock is set to debut Friday, after the U.K.-based mental health care company’s upsized initial public offering price at $17 a share, above .

Their potential is massive and can flip the script for those struggling with mental health disorders. COMPASS Pathways PLC Sponsored ADR has been upgraded to a Zacks Rank #2 , reflecting growing optimism about the company’s earnings prospects. 12 out of 14 patients went into remission for three months following a single 25mg dose of COMP360 psilocybin therapy, in an independent investigator-initiated, exploratory open-label study of type II… Psychedelic stocks have seen remarkable progress in recent years, evolving from a fad to mainstream medicine.

• Several pharmaceutical companies are now investigating their potential therapeutic value.
• Potential short squeeze plays gained steam in 2021 and continued through 2023 with new traders looking for the next huge move.
• Compass Pathways management to meet virtually with Cantor Fitzgerald Virtual Meetings to be held on March hosted by Cantor Fitzgerald.
• The Compass Pathways PLC stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock.

The chart is divided into “candles” that give us information about COMPASS Pathways plc’s stock price action in 1-hour chunks. Each candlestick will display CMPS’s opening price, closing price, as well as the highest and lowest prices that reached within the 1-hour period. This information makes it easier to make an informed price prediction. As far as the long-term COMPASS Pathways plc stock forecast is concerned, here’s what our predictions are currently suggesting. These predictions are based on the 10-year average growth of CMPS.

• In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest.
• Some traders try to identify candlestick patterns when making a stock price prediction to try and get an edge over the competition.
• Featured in The Global Fintech Index 2020 as the top Fintech company of the country.
• Data may be intentionally delayed pursuant to supplier requirements.
• U.S. Treasuries (“T-Bill“) investing services on the Public Platform are offered by Jiko Securities, Inc. (“JSI”), a registered broker-dealer and member of FINRA & SIPC.

This means that analysts believe this stock is likely to outperform the market over the next twelve months. CMPS and their shrooms have been on a downward consolidation for what has felt like a year now. I, like so many others, are looking for signs of accumulation and seller exhaustion before the next step can occur.